Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...
Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.
We are delighted to welcome Stephen to TScan at this stage of growth for the Company,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “His robust commercial leadership experience includes over ...
At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.
Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...
Riyadh, October 12, 2022, SPA -- King Faisal Specialist Hospital & Research Center (KFSHRC) has signed a memorandum of understanding with Kite-Gilead Sciences Company to cooperate in clinical research ...
On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today, I have the pleasure of talking, about cancer with Cindy, who's the Head of Kite. And thank you ...
Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants … ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.
Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback